Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities

Friedlander, Robin; Lazar, Susan; Klancnik, Joseph; Friedlander, R; Lazar, S; Klancnik, J
October 2001
Canadian Journal of Psychiatry;Oct2001, Vol. 46 Issue 8, p741
Academic Journal
journal article
Objective: To study the usage, efficacy, and side effects patterns of atypical neuroleptics (atypicals) in adolescents and young adults with developmental disabilities (DDs) (mental retardation). Method: We undertook a chart review of adolescents and young adults (under age 25 years) seen by our specialized mental health team. Results: Risperidone and olanzapine were by far the most frequently prescribed atypicals. Robust clinical effects were noted for both psychotic and nonpsychotic disorders. Most patients tolerated atypicals well, although a significant minority did experience neuroleptic induced movement disorders (NIMDs), particularly dystonias and dyskinesias. Female patients with DDs appear to be at particular risk of NIMDs. Conclusions: Atypicals are useful in treating various conditions associated with DDs. This population, however, seems particularly sensitive to NIMDs, hence caution and close monitoring are required.


Related Articles

  • Olanzapine use in the elderly: a retrospective analysis. Solomons, Kevin; Geiger, Odie; Solomons, K; Geiger, O // Canadian Journal of Psychiatry;Mar2000, Vol. 45 Issue 2, p151 

    Objective: To evaluate the efficacy and safety of olanzapine in a hospitalized geriatric population that had previously failed to respond to, or tolerate, numerous trials with other antipsychotic medications. Method: A retrospective chart analysis was conducted on 58...

  • Re: treatment noncompliance with orally disintegrating olanzapine tablets. Citrome, Leslie // Canadian Journal of Psychiatry;Jun2004, Vol. 49 Issue 6, p412 

    Presents a letter to the editor related to the treatment of the patients with schizophrenia.

  • Management of treatment-resistant schizophrenia with olanzapine. Thomas, Stephanie G.; Labbate, Lawrence A.; Thomas, S G; Labbate, L A // Canadian Journal of Psychiatry;Mar1998, Vol. 43 Issue 2, p195 

    A letter to the editor is presented regarding management of schizophrenia with olanzapine in a treatment-resistant schizophrenic patient.

  • Aggression, agitation, and mania with olanzapine. John, Vineeth; Rapp, Michael; Pies, Ronald; John, V; Rapp, M; Pies, R // Canadian Journal of Psychiatry;Dec1998, Vol. 43 Issue 10, p1054 

    A letter to the editor is presented in response to the topic on aggression, agitation, and mania with olanzapine.

  • Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Chue, Pierre; Welch, Ron; Binder, Carin // Canadian Journal of Psychiatry;Oct2004, Vol. 49 Issue 10, p701 

    Objective: To investigate the disintegration profile, acceptability, and tolerability of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder.Method: Ten patients stable for at least 10 days on monotherapy with oral...

  • Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Dursun, Serdar M; Gardner, David M; Bird, Diane C; Flinn, Janet; Dursun, S M; Gardner, D M; Bird, D C; Flinn, J // Canadian Journal of Psychiatry;Sep1999, Vol. 44 Issue 7, p701 

    Objective: This prospective, consecutive case-series outcome investigation evaluates the effectiveness of olanzapine in 16 patients with treatment-resistant schizophrenia. Method: Treatment resistance was defined as nonresponsiveness to at least 3 antipsychotic drugs...

  • Antipsychotic drugs and obesity: is prolactin involved? Baptista, Trino; Lacruz, Anny; Meza, Teraiza; Contreras, Quilianio; Delgado, Carlos; Mejias, Maria A; Hernàndez, Luis; Baptista, T; Lacruz, A; Meza, T; Contreras, Q; Delgado, C; Mejìas, M A; Hernàndez, L // Canadian Journal of Psychiatry;Nov2001, Vol. 46 Issue 9, p829 

    Objectives: To correlate the anthropometric indexes (Body Mass Index [BMI] and Waist-Hip ratio [WHR]) with the serum prolactin levels in a heterogeneous population of patients treated with typical antipsychotic (AP) drugs.Methods: We evaluated BMI, WHR, and fasting...

  • Waterborne Risperidone Decreases Stress Response in Zebrafish. Idalencio, Renan; Kalichak, Fabiana; Rosa, João Gabriel Santos; Oliveira, Tiago Acosta de; Koakoski, Gessi; Gusso, Darlan; Abreu, Murilo Sander de; Giacomini, Ana Cristina Varrone; Barcellos, Heloísa Helena de Alcântara; Piato, Angelo L.; Barcellos, Leonardo José Gil // PLoS ONE;10/16/2015, Vol. 10 Issue 10, p1 

    The presence of drugs and their metabolites in surface waters and municipal effluents has been reported in several studies, but its impacts on aquatic organisms are not yet well understood. This study investigated the effects of acute exposure to the antipsychotic risperidone on the stress and...

  • Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. Patel, Nick C.; Crismon, M. Lynn; Pondrom, Michael // Journal of Behavioral Health Services & Research;Oct-Dec2005, Vol. 32 Issue 4, p438 

    One-year rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer alone, a mood stabilizer plus a typical antipsychotic, or a mood stabilizer plus an atypical antipsychotic were examined. Time to rehospitalization was measured by using the product-limit...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics